127 related articles for article (PubMed ID: 8396624)
1. In vitro activity of cefodizime (HR-221) in combination with beta-lactamase inhibitors.
Segatore B; Perilli M; Franceschini N; Setacci D; Oratore A; Amicosante G
J Chemother; 1993 Jun; 5(3):147-50. PubMed ID: 8396624
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of combinations of beta-lactam antibiotics with beta-lactamase inhibitors against cephalosporinase-producing bacteria.
Kitzis MD; Ferré B; Coutrot A; Acar JF; Gutmann L
Eur J Clin Microbiol Infect Dis; 1989 Sep; 8(9):783-8. PubMed ID: 2556277
[TBL] [Abstract][Full Text] [Related]
3. In-vitro evaluation of the four beta-lactamase inhibitors: BRL42715, clavulanic acid, sulbactam, and tazobactam.
Muratani T; Yokota E; Nakane T; Inoue E; Mitsuhashi S
J Antimicrob Chemother; 1993 Sep; 32(3):421-9. PubMed ID: 8262864
[TBL] [Abstract][Full Text] [Related]
4. Activity of 13 beta-lactam agents combined with BRL 42715 against beta-lactamase producing gram-negative bacteria compared to combinations with clavulanic acid, tazobactam and sulbactam.
Piddock LJ; Jin YF; Turner HL
J Antimicrob Chemother; 1993 Jan; 31(1):89-103. PubMed ID: 8383105
[TBL] [Abstract][Full Text] [Related]
5. Comparative activity of beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with beta-lactams against beta-lactamase-producing anaerobes.
Appelbaum PC; Jacobs MR; Spangler SK; Yamabe S
Antimicrob Agents Chemother; 1986 Nov; 30(5):789-91. PubMed ID: 3026241
[TBL] [Abstract][Full Text] [Related]
6. Evolution of beta-lactamase inhibitors.
Rolinson GN
Rev Infect Dis; 1991; 13 Suppl 9():S727-32. PubMed ID: 1656513
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial susceptibilities of Campylobacter jejuni and Campylobacter coli to 12 beta-lactam agents and combinations with beta-lactamase inhibitors.
Tajada P; Gomez-Graces JL; Alós JI; Balas D; Cogollos R
Antimicrob Agents Chemother; 1996 Aug; 40(8):1924-5. PubMed ID: 8843305
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of beta-lactamases by tazobactam and in-vitro antibacterial activity of tazobactam combined with piperacillin.
Higashitani F; Hyodo A; Ishida N; Inoue M; Mitsuhashi S
J Antimicrob Chemother; 1990 Apr; 25(4):567-74. PubMed ID: 2161820
[TBL] [Abstract][Full Text] [Related]
9. Susceptibilities of beta-lactamase-positive and -negative strains of Campylobacter coli to beta-lactam agents.
Lachance N; Gaudreau C; Lamothe F; Turgeon F
Antimicrob Agents Chemother; 1993 May; 37(5):1174-6. PubMed ID: 8390812
[TBL] [Abstract][Full Text] [Related]
10. Effect of beta-lactamase inhibitors on beta-lactamases from anaerobic bacteria.
Hedberg M; Lindqvist L; Tunér K; Nord CE
Eur J Clin Microbiol Infect Dis; 1992 Nov; 11(11):1100-4. PubMed ID: 1338315
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of beta-lactamase inhibitors against clinical isolates of Acinetobacter species.
Suh B; Shapiro T; Jones R; Satishchandran V; Truant AL
Diagn Microbiol Infect Dis; 1995 Feb; 21(2):111-4. PubMed ID: 7628190
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility of clinical isolates to expanded-spectrum beta-lactams alone and in the presence of beta-lactamase inhibitors.
Qadri SM; Ueno Y; Cunha BA
Chemotherapy; 1996; 42(5):334-42. PubMed ID: 8874972
[TBL] [Abstract][Full Text] [Related]
13. Cross-resistance to beta-lactam-beta-lactamase inhibitor combinations and clindamycin among cefoxitin-resistant and cefoxitin-susceptible strains of the Bacteroides fragilis group.
Aldridge KE
Diagn Microbiol Infect Dis; 1993 Oct; 17(3):251-6. PubMed ID: 8112038
[TBL] [Abstract][Full Text] [Related]
14. Influence of beta-lactamase inhibitors on the activity of oxacillin against methicillin-resistant Staphylococcus aureus.
Chang SC; Hsieh WC; Luh KT
Diagn Microbiol Infect Dis; 1995 Feb; 21(2):81-4. PubMed ID: 7628197
[TBL] [Abstract][Full Text] [Related]
15. Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases.
Akova M; Yang Y; Livermore DM
J Antimicrob Chemother; 1990 Feb; 25(2):199-208. PubMed ID: 2158496
[TBL] [Abstract][Full Text] [Related]
16. Variation in the potentiation of beta-lactam antibiotic activity by clavulanic acid and sulbactam against multiply antibiotic-resistant bacteria.
Aldridge KE; Sanders CV; Marier RL
J Antimicrob Chemother; 1986 Apr; 17(4):463-9. PubMed ID: 3011724
[TBL] [Abstract][Full Text] [Related]
17. Beta-lactam/beta-lactamase inhibitor combinations: development, antibacterial activity and clinical applications.
Sutherland R
Infection; 1995; 23(4):191-200. PubMed ID: 8522374
[No Abstract] [Full Text] [Related]
18. Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin.
Aronoff SC; Jacobs MR; Johenning S; Yamabe S
Antimicrob Agents Chemother; 1984 Oct; 26(4):580-2. PubMed ID: 6097169
[TBL] [Abstract][Full Text] [Related]
19. Antibacterial activity of clavulanate and tazobactam on Peptostreptococcus spp.
Reig M; Baquero F
J Antimicrob Chemother; 1994 Feb; 33(2):358-9. PubMed ID: 8182024
[No Abstract] [Full Text] [Related]
20. Interaction of clavulanic acid, sulbactam and cephamycin antibiotics with beta-lactamases.
Grace ME; Fu KP; Gregory FJ; Hung PP
Drugs Exp Clin Res; 1987; 13(3):145-8. PubMed ID: 3040368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
